Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Cboe BZX - 08/14 05:57:22 pm
66.465 USD   -0.38%
08/13Roundup cancer verdict sends Bayer shares sliding
RE
08/13Roundup cancer verdict sends Bayer shares sliding
RE
08/10MERCK AND : Head of Human Resources Mirian M. Graddick-Weir to Retir..
AQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
08/07/2018 08/08/2018 08/09/2018 08/10/2018 08/14/2018 Date
66.58(c) 66.69(c) 66(c) 66.07(c) 66.47 Last
8 083 568 6 509 331 7 151 836 7 439 672 1 883 479 Volume
+0.54% +0.17% -1.03% +0.11% -0.37% Change
More quotes
Financials (USD)
Sales 2018 42 396 M
EBIT 2018 13 784 M
Net income 2018 7 014 M
Debt 2018 15 241 M
Yield 2018 2,91%
Sales 2019 43 653 M
EBIT 2019 14 693 M
Net income 2019 9 994 M
Debt 2019 12 025 M
Yield 2019 3,03%
P/E ratio 2018 25,86
P/E ratio 2019 17,52
EV / Sales2018 4,50x
EV / Sales2019 4,30x
Capitalization 176 B
More Financials
Company
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances.The Pharmaceutical... 
Sector
Pharmaceuticals
Calendar
09/14Ex-dividend day for
More about the company
Surperformance© ratings of Merck and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on MERCK AND COMPANY
08/13Roundup cancer verdict sends Bayer shares sliding
RE
08/13Roundup cancer verdict sends Bayer shares sliding
RE
08/10MERCK AND : Head of Human Resources Mirian M. Graddick-Weir to Retire, Steven C...
AQ
08/09EISAI : and Merck Announce FDA Grants Breakthrough Therapy Designation for LENVI..
AQ
08/09MERCK AND : - Selumetinib Granted Orphan Designation in Europe for Neurofibromat..
AQ
08/09MERCK AND : AstraZeneca - Selumetinib granted orphan designation in Europe for n..
AQ
08/08Merck's Zepatier price cut lands it co-exclusive status on Express Scripts 20..
AQ
08/07MERCK : ’s Head of Human Resources Mirian M. Graddick-Weir to Retire; Stev..
BU
08/07MERCK AND : Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation..
AQ
08/07MERCK AND : Eisai`s Lenvima posts big growth numbers as Merck collaboration roll..
AQ
More news
Sector news : Pharmaceuticals - NEC
05:47aNOVARTIS : recruits new compliance head from Siemens after ethics stumbles
RE
05:04aEXCLUSIVE : Carlyle starts preparations for $5 billion listing of chemicals grou..
RE
02:48aBAYER : Verdict In Weed Killer Case Hits Bayer -- WSJ
DJ
02:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
08/13BIOGEN : pricey muscle drug Spinraza too costly for Britain
RE
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on MERCK AND COMPANY 
MERCK & CO., INC. - 2013
A resistance as obstacle
SELL
More Strategies
Latest Tweets
10:06aYesterday's DJIA Market movers Advanced $MRK +0.98% $AAPL +0.65% $V +0.34% .. 
06:10aThey are offered the Merck vaccine. The problem occurs in the time before it..
1
08/13Merck KGaA is celebrating its 350th anniversary with a competition to identif..
2
08/13From zero to hero: J&J ceo praises Trump one year after criticizing him.... 
08/13 have officially placed WR Robert Davis on reserve/injured list. In a corres.. 
More tweets
Qtime:343
News from SeekingAlpha
08/13TherapeuticsMD Announces FDA Approval For Year-Round Contraceptive Ring 
08/123 THINGS IN BIOTECH, AUGUST 12 : Sesen's Bladder Cancer Therapy Get Moving 
08/11You Should Not Miss Bristol-Myers Squibb In 2018 
08/11STOCKS TO WATCH : Any Privacy For Tesla? 
08/10FDA OKs birth control app 
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 70,5 $
Spread / Average Target 5,7%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY17.42%175 715
JOHNSON & JOHNSON-6.42%350 770
PFIZER13.00%239 423
NOVARTIS-0.87%209 596
ROCHE HOLDING LTD.-3.39%207 317
AMGEN11.80%125 843